| |
Newsroom /
Health and Fitness
/
Healthcare
/
Colorectal Cancer - Pipeline Assessment and Market Forecasts to 2020
Colorectal Cancer - Pipeline Assessment and Market Forecasts to 2020
The Global Colorectal Cancer Therapeutics Market was Worth $7.0 billion in 2009, Driven by the Growth in the Patient Volume and Annual Cost of Colorectal Cancer Therapy
Hyderabad,
AP,
India
(prbd.net)
26/10/2010
GlobalData analysis found that, in 2009, the global colorectal cancer therapeutics market was worth $7.0 billion. Between 2001 and 2009, the market grew at a rate of 27.6%. By 2020, the market is expected to be worth $8.8 billion, indicating a Compound Annual Growth Rate (CAGR) of 2.1% between 2009 and 2020.
The global colorectal cancer therapeutics market is very attractive and has primarily been driven by the growth in patient volume and the annual cost of therapy. The patient volume was driven by increased affordability rates and growth in treatment usage patterns such as the diseased population, treatment seeking population, diagnosis population and prescription population. The annual cost of colorectal cancer therapy was driven by the launch of new therapies such as oxaliplatin, capecitabine, bevacizumab
and cetuximab. Further, the annual cost of therapy was also driven by the increased adoption of combination therapies such as FOLFOX (5-fluorouracil, leucovorin and oxaliplatin), FOLFIRI (5-fluorouracil, leucovorin and irinotecan), 5FU/LV (5-fluorouracil, leucovorin) and CAPOX (capecitabine and oxaliplatin) in the first-line and second-line treatment of metastatic colorectal cancer patients.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Colorectal-Cancer-Pipeline-Assessment-and-Market-Forecasts-to-2020&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Bevacizumab, in combination with FOLFOX therapy, became the standard of care for the first-line treatment of metastatic colorectal cancer patients. Similarly, cetuximab in combination with FOLFIRI became one of the most common prescribed treatments for metastatic colorectal cancer patients with the KRAS wildtype. In 2009, the US was the leading market in the global colorectal cancer therapeutics market with an estimated market share of 54.8%. Japan was the second leading market with an approximate market
share of 13.4%, closely followed by France with an approximate market share of 9.6%.
GlobalData, the industry analysis specialist’s new report, “Colorectal Cancer - Pipeline Assessment and Market Forecasts to 2020” is an essential source of information and analysis on the global colorectal cancer market. The report identifies the key trends shaping and driving the global colorectal cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most
importantly, the report provides valuable insight on the pipeline products within the global colorectal cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Colorectal-Cancer-Pipeline-Assessment-and-Market-Forecasts-to-2020&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|